Status:
RECRUITING
HIV Resistance, Molecular Epidemiology and New Treatment Strategies in the Eastern European Region and in Russia
Lead Sponsor:
Euresist Network GEIE
Collaborating Sponsors:
Karolinska Institutet
University of Siena
Conditions:
HIV-1-infection
Eligibility:
All Genders
18+ years
Brief Summary
Cohort based prospective monitoring of the spread of HIV drug resistance during a phase when new anti-HIV drugs are introduced.
Detailed Description
The patient cohort that has been set up includes both viral sequences and clinical/epidemiological data from diverse geographical regions in Russia and Ukraine, where continued prospective follow-up -...
Eligibility Criteria
Inclusion
- naïve patients starting 2nd generation INSTI treatment
- first line patients under 2nd generation INSTI treatment with either viral RNA sequence before therapy start, or PBMC available with PBMC sample date not more than 3 years from therapy start date (with reasonably sure history of no failure in the interval from therapy start date to PBMC sample date\]).
Exclusion
- patients not having a signed informed consent for the EIDB data repository, if required by local/national legislation in order to have data in the common data repository.
- patients not having Signed Informed consent for the present study, if required by local authorities iii) Persons aged \< 18 at baseline
Key Trial Info
Start Date :
December 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06127290
Start Date
December 1 2021
End Date
May 31 2025
Last Update
February 27 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Cologne
Cologne, Germany
2
University Hospital of Siena
Siena, Italy
3
Pomeranian Medical University Szczecin
Szczecin, Poland
4
Karolinska Institutet
Stockholm, Sweden